The short version of reversed-phase HPLC fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-12-13 and is reviewed periodically as new material appears.
TB-500 is a synthetic peptide preparation marketed under a name derived from thymosin beta-4, a 43-residue actin-binding protein first isolated from thymus tissue. The full-length protein has a reported molecular mass near 4963 Da, while material sold as TB-500 is often described as a fragment containing the actin-binding motif LKKTETQ. Because suppliers use the name inconsistently, published sources sometimes refer to the same label as a fragment, a synthetic copy, or a related analog. This naming ambiguity complicates direct comparison of reports across studies.
Laboratory work on thymosin beta-4 describes binding to monomeric actin and effects on cell migration, angiogenesis, and inflammatory signaling in cultured cells. Animal models have examined skin, corneal, and cardiac repair after injury, with outcomes reported mainly in preclinical literature. Most of that evidence concerns the parent protein rather than preparations labelled TB-500, so extrapolation from animal findings to a specific commercial product remains uncertain. Whether the two behave identically in living systems has not been established in controlled human studies.
No major regulatory agency has approved TB-500 for therapeutic use, and it holds no pharmacopoeial monograph. The name appears on the World Anti-Doping Agency prohibited list within the class covering peptide hormones, growth factors, and related substances. Detection in doping control relies on mass spectrometric methods applied to urine, often after preparation steps that concentrate the analyte. Discussion of TB-500 therefore clusters in biochemistry, sports medicine, and anti-doping literature rather than in registered clinical trials.
Dry peptide powder is commonly kept at −20 °C in a desiccated container away from light, a practice that limits moisture uptake and oxidation. Once dissolved, solutions are generally held at 2–8 °C for short periods or frozen at −20 °C or lower for longer storage, with repeated freeze-thaw cycles avoided. Hydrolysis and oxidation are the main degradation routes for peptides in solution, and both accelerate at higher temperature or extreme pH. Published stability data specific to TB-500 are limited, so shelf life should be treated as uncertain.
Identity and purity checks for peptide material typically combine reversed-phase high-performance liquid chromatography with mass measurement, since retention time alone cannot confirm a sequence. Mass measurement verifies the expected molecular mass within instrument tolerance, while chromatographic peak area provides a purity estimate. Anti-doping analysis of urine uses related but more sensitive workflows, sometimes after solid-phase extraction. For research material, batch documentation, certificate content, and independent testing are common points of scrutiny, because supply chains outside pharmaceutical regulation vary widely in the paperwork they provide.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | Approximately 4963 Da for full-length thymosin beta-4 | Value applies to the parent protein; fragment products may differ |
| Appearance | White to off-white lyophilized powder | Typical form of supplied synthetic peptide |
| Solubility | Freely soluble in water | Polar peptide; dissolves readily in aqueous buffer |
| Storage of dry powder | −20 °C, desiccated, protected from light | Standard laboratory practice for peptides |
| Typical detection method | Liquid chromatography–tandem mass spectrometry | Used in purity testing and anti-doping analysis |
TB-500 is a catalogue name applied to a synthetic peptide related to thymosin beta-4, an actin-binding protein found in most mammalian cells. Suppliers do not use the label consistently: some describe it as the full 43-residue protein, others as a short fragment from the actin-binding region, and others as a related tetrapeptide. Because the name is commercial rather than chemical, two products sold under it may not contain the same molecule. This naming ambiguity is the first point to check in any description of the material.
The most frequently cited identity is a seven-residue fragment with the sequence LKKTETQ, taken from the actin-binding domain of the parent protein. A separate molecule, N-acetyl-seryl-aspartyl-lysyl-proline, often shortened to Ac-SDKP, derives from the same protein's N-terminal region and appears in overlapping literature. Reported molecular masses therefore differ between sources, and a mass value on its own does not establish which fragment is present. Confirmation requires a defined sequence rather than a single number.
Research interest in thymosin beta-4 fragments centres on actin sequestration, cell migration and tissue repair models. Most published work uses cultured cells or animal wound and cardiac preparations, and findings are generally described as preliminary. No fragment of this protein has been approved as a therapeutic product by major regulators. Reviews of the field note inconsistent dosing, delivery routes and outcome measures across studies, which complicates direct comparison. The material is best understood as a laboratory reagent with an active but unresolved research literature.
Purity and identity are separate measurements and are often confused. Reverse-phase high-performance liquid chromatography, usually with ultraviolet detection near 214 nanometres, reports the share of total peak area belonging to the target compound. Mass spectrometry by electrospray or matrix-assisted laser desorption then checks whether the observed mass matches the expected sequence. Neither measurement alone shows that a vial holds the intended peptide. Peptide content, meaning the fraction of vial mass that is genuine peptide rather than counter-ion, water or residual acid, is reported separately and is frequently lower than the stated purity figure.
The regulatory position is broadly consistent across major jurisdictions: no thymosin beta-4 fragment is an approved medicine, and laboratory material is commonly labelled as not intended for human consumption. Anti-doping rules in sport list thymosin beta-4 and its fragments among prohibited peptide hormones. Because these products travel through research-chemical channels rather than pharmaceutical supply chains, quality varies considerably between vendors. Independent testing of identity, purity and sterility is the only dependable check, and a certificate of analysis describes one batch rather than a supplier's whole catalogue.
Lyophilized peptide powder is normally held desiccated at −20 °C, with −80 °C used for longer storage periods. Allowing a sealed vial to reach room temperature before opening is standard practice, because condensation forming on cold powder introduces moisture. Once dissolved, solutions are typically kept cold and shielded from light. Repeated freeze-thaw cycles are avoided because they encourage aggregation and gradual loss of material. These conventions are general to synthetic peptides rather than unique to any one sequence.
TB-500 is a short synthetic peptide sold under a trade name rather than a systematic chemical name. Suppliers usually describe it as a fragment of thymosin beta-4 and ship it as a lyophilised powder intended for laboratory use. Because the label is commercial, the exact sequence attributed to it is not fully consistent across catalogues, and some listings present a seven-residue peptide while others describe related fragments of similar length. It is not an approved medicine in any major jurisdiction, and it is handled as a research chemical.
Thymosin beta-4 itself is a natural peptide of 43 residues found in many cell types and body fluids. Its best-characterised function is binding and sequestering actin monomers, which influences cytoskeletal dynamics. The sequence most often associated with TB-500, LKKTETQ, corresponds to part of that actin-binding region. A different fragment, Ac-SDKP, is also derived from the same parent peptide and is studied in its own right, which is one reason discussions of thymosin fragments can become confusing. The two are structurally distinct and are not interchangeable.
Interest in the fragment grew during the 1990s and 2000s, when it moved from laboratory work into sports and supplement markets. Anti-doping bodies added thymosin beta-4 fragments to prohibited lists, and a small number of adverse analytical findings have been reported in competition testing. Published controlled human trials remain scarce. Most mechanistic evidence comes from cell culture and animal models, and those studies examine endpoints such as cell migration, wound closure and inflammation markers. That evidence supports research interest but does not establish clinical benefit, and broad regenerative claims should be read as unverified.
== History == C17α esters of 11-deoxycortisol were unexpectedly found to possess antiandrogenic activity. Clascoterone, also known as cortexolone 17α-propionate, was selected for development based on its optimal drug profile. The medication was approved by the US Food and Drug Administration (FDA) for the treatment of acne in August 2020. The FDA approved clascoterone based on evidence from two clinical trials (Trial 1/NCT02608450 and Trial 2/NCT02608476) of 1,440 participants 9 to 58 years of age with acne vulgaris. The trials were conducted at 99 sites in the United States, Poland, Romania, Bulgaria, Ukraine, Georgia, and Serbia. Participants applied clascoterone or vehicle (placebo) cream twice daily for 12 weeks. Neither the participants nor the health care providers knew which treatment was being given until after the trial was completed. The benefit of clascoterone in comparison to placebo was assessed after 12 weeks of treatment using the Investigator's Global Assessment (IGA) score that measures the severity of disease (on a scale from 0 to 4) and a decrease in the number of acne lesions.
== Career and Discoveries == In 2000, Sen joined The Ohio State University, where he was promoted to full professor with tenure in 2004 and later awarded the John H. & Mildred C. Lumley Endowed Chair of Surgery. At Ohio State, he also served as Associate Dean of Research. Sen was the founding Executive Director of the OSU Comprehensive Wound Center and the founding Director of the OSU Center for Regenerative Medicine & Cell-Based Therapies. His research at Ohio State focused on tissue injury, repair, regeneration, and infection, including studies on stroke, tissue reprogramming, and cutaneous wound healing. This work led to the development of Tissue Nanotransfection (TNT) technology for in vivo tissue reprogramming, published in Nature Nanotechnology. TNT received a 2018 Edison Awards for Innovation. Sen's work also advanced electroceutical approaches for managing tissue infection, earning the Frost & Sullivan Award for New Product Innovation. In 2021, he was elected a Lifetime Fellow of the National Academy of Inventors. In 2018, the Indianapolis Business Journal described Sen as “one of the world's leading experts in the nascent field of regenerative medicine” when he joined Indiana University as Director of the Indiana Center for Regenerative Medicine and Engineering (ICRME), Executive Director of IU Health Comprehensive Wound Center, J. Stanley Battersby Chair and Professor of Surgery, Associate Vice President of Research, and Associate Dean for Entrepreneurial Research. He brought a team of 30 researchers and $10 million in research funding.
At first glance, this result would seem to contradict the assertion that states choose alliance partners in order to balance against the strongest. Focusing solely on aggregate power would lead us to expect more states to ally with the Soviet Union, in order to prevent the United States from using its superior overall resources in harmful ways. Judging from the preponderance of aggregate power favoring the West, many states appear to have 'bandwagoned' rather than balanced by aligning with the United States. This is even more striking when one remembers that the United States was overwhelmingly the world's most powerful country in the immediate postwar period, yet was able to bring most of the other industrial powers into alignment with rather than against it. In 1986, still not envisaging the end of the Cold War in sight, Zbigniew Brzezinski emphasized the historical uniqueness of the current period regarding the preponderance of power: "[N]ever before would the eclipse of one of the major rival powers have given to the other effective global preponderance." Shortly after one of the rival superpowers eclipsed, the Pentagon Regional Defense Strategy (1992) formulized: "It is not in our interest … to return to earlier periods in which multiple military powers balanced one against another in what passed for security structures, while regional or even global peace hang in the balance." In the first post-Cold War year, Leffler advocated for the United States to continue its strategy of "preponderance of power".
== Impacts by region == Observations of ENSO events since 1950 show that impacts associated with such events depend on the time of year. While some events and impacts are expected to occur, it is not certain that they will happen. The impacts that generally do occur during most El Niño events include below-average rainfall over Indonesia and northern South America, and above average rainfall in southeastern South America, eastern equatorial Africa, and the southern United States.
Sources: en.wikipedia.org
Radioactive substances can harm human health via (i) local skin contamination, (ii) internal exposure due to ingestion of radioactive isotopes, and (iii) external overexposure by β-activity and γ-radiation. Together with radium and transuranium elements, actinium is one of the most dangerous radioactive poisons with high specific α-activity. The most important feature of actinium is its ability to accumulate and remain in the surface layer of skeletons. At the initial stage of poisoning, actinium accumulates in the liver. Another danger of actinium is that it undergoes radioactive decay faster than being excreted. Adsorption from the digestive tract is much smaller (~0.05%) for actinium than radium. Protactinium in the body tends to accumulate in the kidneys and bones. The maximum safe dose of protactinium in the human body is 0.03 μCi that corresponds to 0.5 micrograms of 231Pa. This isotope, which might be present in the air as aerosol, is 2.5×108 times more toxic than hydrocyanic acid. Plutonium, when entering the body through air, food or blood (e.g. a wound), mostly settles in the lungs, liver and bones with only about 10% going to other organs, and remains there for decades. The long residence time of plutonium in the body is partly explained by its poor solubility in water. Some isotopes of plutonium emit ionizing α-radiation, which damages the surrounding cells.
=== Heroin epidemic === During the Nixon administration, the country faced a heroin epidemic. There were 15 times as many heroin addicts in Washington, D.C., as there were in all of England. The US government responded in two ways. The first response came from Nixon's newly appointed Special Action Office for Drug Abuse Prevention, headed by Jerome Jaffe to provide free synthetic alternatives to heroin in the form of government-regulated methadone. The idea was not to cure the addicts but to prevent them from engaging in street crimes to feed their addictions. The second response came in the form of an increased police presence. Some community activists criticized the Nixon treatment program, many of whom saw heroin addiction and methadone treatment as a new form of black oppression. There was a call from black community leaders for more punitive action against dealers and users. Black activists in Chicago, DC, and Harlem called on government to increase the policing and the sentencing for individuals involved in robbery, mugging, street dealing and murder. Many civil rights advocates pushed back against the law and order rhetoric that won Nixon the White House, but other activists from some of the most drug-affected cities were some of the earliest supporters of more punitive drug policies. Scholars argue that conservative politicians used the calls from the nation's urban leaders as proof that the law and order policies had nothing to do with race. Many historians, including Foreman Jr.
The British governor Stamford Raffles arrived in Singapore on 28 January 1819 and soon recognised the island as a natural choice for the new port. The island was then nominally ruled by Tengku Abdul Rahman, the Sultan of Johor, who was controlled by the Dutch and the Bugis. However, the Sultanate was weakened by factional division: Abdul Rahman, the Temenggong of Johor to Tengku Abdul Rahman, as well as his officials, were loyal to the Sultan's elder brother Tengku Long, who was living in exile in Penyengat Island, Riau Islands. With the Temenggong's help, Raffles managed to smuggle Tengku Long back into Singapore. Raffles offered to recognise Tengku Long as the rightful Sultan of Johor, under the title of Sultan Hussein, as well as provide him with a yearly payment of $5000 and another $3000 to the Temenggong; in return, Sultan Hussein would grant the British the right to establish a trading post on Singapore. The Treaty of Singapore was signed on 6 February 1819. In 1824, a further treaty with the Sultan led to the entire island becoming a part of the British Empire. In 1826, Singapore became part of the Straits Settlements, then under the jurisdiction of British India. Singapore became the regional capital in 1836. Prior to Raffles' arrival, there were only about a thousand people living on the island, mostly indigenous Malays along with a handful of Chinese. By 1860 the population had swelled to over 80,000, more than half being Chinese. Many of these early immigrants came to work on the pepper and gambier plantations.
Sources: en.wikipedia.org
Not necessarily. TB-500 is a commercial label that suppliers apply to synthetic peptides described as thymosin beta-4 or a fragment of it. Published research most often studies the full-length protein, so statements about one do not automatically transfer to the other.
No. No major regulatory authority lists an approved product under this name, and no pharmacopoeial monograph exists for it. Material sold under the label is therefore supplied outside approved pharmaceutical channels, which affects the quality documentation available.
It falls within a prohibited class covering peptide hormones and growth factors, based on presumed effects on tissue repair and blood vessel formation. Anti-doping laboratories have published mass spectrometry methods for detecting thymosin beta-4 related peptides in urine samples.
Standard practice is a desiccated container at −20 °C, protected from light and kept sealed between uses. Letting the vial reach room temperature before opening reduces condensation on the powder. Repeated warming and cooling of the whole container is generally avoided.